Drugplain

Guanfacine 4 mg/1

Guanfacine · TABLET, EXTENDED RELEASE · Sun Pharmaceutical Industries, Inc

4 Recalls on RecordCurrently in Shortage
Plain English

Guanfacine is a tablet, extended release containing guanfacine at 4 mg/1, taken oral. Manufactured by Sun Pharmaceutical Industries, Inc.

Key Facts

Brand Name
Guanfacine
Generic Name
Guanfacine
NDC Code (Product)
63304-927
Manufacturer
Sun Pharmaceutical Industries, Inc
Strength
4 mg/1
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Marketing Status
Application #
ANDA205689
Marketing Start
08/17/2018

Recall History

4 Recalls on Record
Class II07/02/2013

Aidapak Services, LLC

Labeling: Label Mixup: guanFACINE HCl, Tablet, 1 mg may have potentially been mislabeled as one of the following drugs: buPROPion HCl ER, Tablet, 200 mg, NDC 47335073886, Pedigree: W002727, EXP: 6/6/2014; OMEGA-3 FATTY ACID, Capsule, 1000 mg, NDC 00904404360, Pedigree: AD39588_7, EXP: 5/13/2014; OMEPRAZOLE/SODIUM BICARBONATE, Capsule, 20 mg/1,100 mg, NDC 11523726503, Pedigree: W003873, EXP: 6/2

TerminatedVoluntary: Firm initiated
Class II07/02/2013

Aidapak Services, LLC

Labeling:Label Mixup; guanFACINE HCl Tablet, 2 mg may be potentially mislabeled as buPROPion HCl ER, Tablet, 200 mg, NDC 47335073886, Pedigree: AD21790_4, EXP: 5/1/2014; AMANTADINE HCL, Capsule, 100 mg, NDC 00781204801, Pedigree: W002997, EXP: 6/11/2014; glyBURIDE, Tablet, 1.25 mg, NDC 00093834201, Pedigree: W003677, EXP: 2/28/2014; ACYCLOVIR, Capsule, 200 mg, NDC 00093894001, Pedigree: AD60

TerminatedVoluntary: Firm initiated
Class II03/31/2021

Apotex Corp.

Cross Contamination with Other Product: Product is being recalled due to Trace Amounts of Quetiapine Fumarate

OngoingVoluntary: Firm initiated
Class II07/02/2013

Aidapak Services, LLC

Labeling: Label Mixup: guanFACINE HC, Tablet, 1 mg may have potentially been mislabeled as one of the following drugs: glyBURIDE, Tablet, 2.5 mg, NDC 00093834301, Pedigree: AD46265_22, EXP: 5/15/2014; FOSINOPRIL SODIUM, Tablet, 10 mg, NDC 60505251002, Pedigree: AD46414_19, EXP: 5/16/2014; chlorproMAZINE HCl, Tablet, 100 mg, NDC 00832030300, Pedigree: AD70629_4, EXP: 5/29/2014; guanFACINE HCl,

TerminatedVoluntary: Firm initiated

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

drug ineffective535 reports
off label use377 reports
somnolence215 reports
aggression212 reports
fatigue197 reports
toxicity to various agents188 reports
hypotension179 reports
nausea172 reports
anxiety163 reports
insomnia156 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

INDICATIONS AND USAGE Guanfacine Tablets, USP are indicated in the management of hypertension. Guanfacine hydrochloride may be given alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.

Dosage & Administration

DOSAGE AND ADMINISTRATION The recommended initial dose of guanfacine hydrochloride when given alone or in combination with another antihypertensive drug is 1 mg daily given at bedtime to minimize somnolence. If after 3 to 4 weeks of therapy 1 mg does not give a satisfactory result, a dose of 2 mg may be given, although most of the effect of guanfacine hydrochloride is seen at 1 mg (see CLINICAL PHARMACOLOGY ). Higher daily doses have been used, but adverse reactions increase significantly with doses above 3 mg/day. The frequency of rebound hypertension is low, but it can occur. When rebound occurs, it does so after 2 - 4 days, which is delayed compared with clonidine hydrochloride. This is consistent with the longer half-life of guanfacine. In most cases, after abrupt withdrawal of guanfacine, blood pressure returns to pretreatment levels slowly (within 2 - 4 days) without ill effects.

Contraindications

CONTRAINDICATIONS Guanfacine Tablets, USP is contraindicated in patients with known hypersensitivity to guanfacine hydrochloride.

Drug Interactions

Drug Interactions The potential for increased sedation when guanfacine hydrochloride is given with other CNS-depressant drugs should be appreciated. The administration of guanfacine concomitantly with a known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration. In such cases, therefore, more frequent dosing may be required to achieve or maintain the desired hypotensive response. Further, if guanfacine is to be discontinued in such patients, careful tapering of the dosage may be necessary in order to avoid rebound phenomena (see Rebound above). Anticoagulants Ten patients who were stabilized on oral anticoagulants were given guanfacine, 1 - 2 mg/day, for 4 weeks. No changes were observed in the degree of anticoagulation. In several well-controlled studies, guanfacine was administered together with diuretics with no drug interactions reported. In the long-term safety studies, guanfacine hydrochloride was given concomitantly with many drugs without evidence of any interactions. The principal drugs given (number of patients in parentheses) were: cardi

Adverse Reactions

ADVERSE REACTIONS Adverse reactions noted with guanfacine hydrochloride are similar to those of other drugs of the central α 2 -adrenoreceptor agonist class: dry mouth, sedation (somnolence), weakness (asthenia), dizziness, constipation, and impotence. While the reactions are common, most are mild and tend to disappear on continued dosing. Skin rash with exfoliation has been reported in a few cases; although clear cause and effect relationships to guanfacine hydrochloride could not be established, should a rash occur, guanfacine hydrochloride should be discontinued and the patient monitored appropriately. In the dose-response monotherapy study described under CLINICAL PHARMACOLOGY , the frequency of the most commonly observed adverse reactions showed a dose relationship from 0.5 to 3 mg as follows: Adverse Reaction Placebo n=59 0.5 mg n=60 1 mg n=61 2 mg n=60 3 mg n=60 Dry Mouth 0% 10% 10% 42% 54% Somnolence 8% 5% 10% 13% 39% Asthenia 0% 2% 3% 7% 3% Dizziness 8% 12% 2% 8% 15% Headache 8% 13% 7% 5% 3% Impotence 0% 0% 0% 7% 3% Constipation 0% 2% 0% 5% 15% Fatigue 2% 2% 5% 8% 10% The percent of patients who dropped out because of adverse reactions are shown below for each dosage group

Frequently Asked Questions

What is Guanfacine used for?

Guanfacine contains Guanfacine. It is a tablet, extended release taken oral. Consult your doctor for specific uses.

Is Guanfacine a controlled substance?

Guanfacine is not classified as a controlled substance by the DEA.

What is the generic name for Guanfacine?

The generic name for Guanfacine is Guanfacine. There are 8 other brand versions of Guanfacine.

What is the NDC code for Guanfacine 4 mg/1?

The NDC (National Drug Code) for Guanfacine 4 mg/1 is 63304-927, listed by Sun Pharmaceutical Industries, Inc.